FindTrial
Sign In

Nivolumab & Ipilimumab

DRUG7 trials

Sponsors

University College, London, Vivace Therapeutics, Inc, Lantern Pharma Inc., The First Affiliated Hospital of Guangzhou Medical University, Guliz Ozgun

Conditions

Advanced Kidney CancerAdvanced MelanomaAdvanced Solid TumorDDR Gene MutationGBMLung Cancer - Non Small CellMelanoma (Skin Cancer)Mesothelioma

Phase 1

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
RecruitingNCT04665206
Vivace Therapeutics, IncMesothelioma, NSCLC, Solid Tumor, Adult
Start: 2021-03-24End: 2030-03-02Target: 434Updated: 2026-04-02
Study of LP-184 in Patients With Advanced Solid Tumors
Active, not recruitingNCT05933265
Lantern Pharma Inc.Advanced Solid Tumor, DDR Gene Mutation, GBM +4
Start: 2023-06-09End: 2026-07-28Updated: 2026-05-04
Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma
RecruitingNCT07501117
Inge Marie SvaneUveal Melanoma
Start: 2026-06-29End: 2029-06-01Target: 15Updated: 2026-07-01

Phase 2

Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature
Active, not recruitingNCT03061539
University College, LondonProstate Cancer
Start: 2018-02-06End: 2027-06-30Updated: 2022-09-28
Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)
RecruitingNCT06926790
The First Affiliated Hospital of Guangzhou Medical UniversityLung Cancer - Non Small Cell
Start: 2025-02-17End: 2030-10-31Target: 69Updated: 2025-04-22

Phase 3

The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.
Not yet recruitingNCT07338981
Guliz OzgunAdvanced Kidney Cancer
Start: 2026-04-30End: 2032-12-31Target: 142Updated: 2026-01-14
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma
Not yet recruitingNCT07815574
Scancell LtdAdvanced Melanoma, Melanoma (Skin Cancer), Metastatic Melanoma +1
Start: 2026-12-01End: 2032-12-01Target: 550Updated: 2026-09-11

Related Papers

Quantitative characterization of platelet count and alanine aminotransferase dynamics to inform personalized dosing in the first-in-human LP-184 trial.
2026-08-12
A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors.
2026-07-07
A first-in-human phase 1a study of LP-184, a tumor site–activated novel alkylating agent, in patients with advanced solid tumors.
Journal of Clinical Oncology2026-05-28
Phase 1a Evaluation of LP-184 in Recurrent Glioblastoma: Safety, Pharmacokinetics, and Translational Optimization of CNS Exposure
medRxiv2026-04-24
Abstract CT116: Data-driven characterization of platelet count and alanine aminotransferase dynamics in the first-in-human LP-184 dose escalation trial
Cancer Research2026-04-17
EXTH-28. Targeting DNA repair mechanisms with spironolactone to enhance LP-184 CNS pharmacodynamics and efficacy
Neuro-Oncology2025-11-01
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.
2025-10-197 citations
Abstract 4728: The selective Yap/Tead inhibitor TY-1054 re-sensitizes acquired resistance to multiple tyrosine kinase-based targeted therapies
Cancer Research2025-04-21
CTNI-29. A PHASE 1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND OBJECTIVE RESPONSE OF LP-184 ALONE AND IN COMBINATION WITH SPIRONOLACTONE IN IDH WILD TYPE GLIOBLASTOMA AT FIRST PROGRESSION
Neuro-Oncology2024-11-01
Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial.
Journal of Clinical Oncology2024-06-017 citations
Abstract LB033: Identification of small molecule Pan-TEAD inhibitors disrupting YAP-TEAD protein-protein interaction and targeting gastric cancer cells
Cancer Research2024-04-051 citations
Abstract 4491: TY-0584: A potent, orally available small molecule YAP/TEAD inhibitor, exhibits anti-tumor effects <i>in vitro</i> and <i>in vivo</i>
Cancer Research2023-04-043 citations
Randomised phase II trial of stereotactic body radiotherapy in combination with<b>check</b>point inhibitors in metastatic castration-resistant<b>pro</b>state cancer (CheckPRO): a study protocol
BMJ Open2023-01-013 citations
Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature (NEPTUNES).
Journal of Clinical Oncology2019-05-206 citations
Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.
2017-10-0149 citations